#doi

Collection of doi news, found 37 news.

ANANDA Scientific and NYU Grossman School of Medicine announce first patient enrolled in the clinical trial for opioid sparing in participants with radiculopathic pain

ANANDA Scientific and NYU Grossman School of Medicine announce first patient enrolled in the clinical trial for opioid sparing in participants with radiculopathic pain

  • 9th March 2022

ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the ...

LintonPharm announces first patient dosed in Phase 1 clinical trial of catumaxomab for Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin

LintonPharm announces first patient dosed in Phase 1 clinical trial of catumaxomab for Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin

  • 2nd December 2021

LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell ...

Olympus strengthens surgical portfolio with the launch of POWERSEAL advanced bipolar surgical energy devices

Olympus strengthens surgical portfolio with the launch of POWERSEAL advanced bipolar surgical energy devices

  • 22nd September 2021

Olympus Corporation (Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced the launch of the ...

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

  • 15th June 2021

infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1 Incheon, South Korea--(Antara/Business ...

LintonPharm announces authorization from China health authority (NMPA) to proceed with a phase 1/2 trial evaluating catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

LintonPharm announces authorization from China health authority (NMPA) to proceed with a phase 1/2 trial evaluating catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

  • 15th April 2021

LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell ...

Humanigen Australia Proprietary Limited established to facilitate Asia-Pacific growth plans

Humanigen Australia Proprietary Limited established to facilitate Asia-Pacific growth plans

  • 24th November 2020

Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and ...

Viet Nam global value chains: creating more value added to local economy from rising exports is a remaining question to tackle by the government, says ASEAN-Japan Centre

Viet Nam global value chains: creating more value added to local economy from rising exports is a remaining question to tackle by the government, says ASEAN-Japan Centre

  • 14th May 2020

- While Viet Nam —­ one of the poorest nations in the world in the 1980s — has become today a market-based and ...

Aptorum Group commences commercialization of dioscorea opposita bioactive nutraceutical tablets and signed sales distribution agreement in Hong Kong

Aptorum Group commences commercialization of dioscorea opposita bioactive nutraceutical tablets and signed sales distribution agreement in Hong Kong

  • 25th February 2020

- Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel ...

JAMA publishes greatly anticipated phase III study using 22nd Century's SPECTRUM® Very Low Nicotine Content cigarettes

JAMA publishes greatly anticipated phase III study using 22nd Century's SPECTRUM® Very Low Nicotine Content cigarettes

  • 6th September 2018

- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and ...

New material kills E. Coli bacteria in 30 seconds

New material kills E. Coli bacteria in 30 seconds

  • 4th June 2016

Every day, we are exposed to millions of harmful bacteria that can cause infectious diseases, such as the E. coli ...

Treatment results of SIR-Spheres® Y-90 resin microspheres are similar regardless of patient age, new publication shows

Treatment results of SIR-Spheres® Y-90 resin microspheres are similar regardless of patient age, new publication shows

  • 3rd February 2016

-606-patient MORE Study Sub-Group Analysis Examined Outcomes for Elderly (≥70 years) and Very Elderly (≥75 ...

Clinicians Worldwide Confirm Impact of UpToDate on Quality of Care in 2014

Clinicians Worldwide Confirm Impact of UpToDate on Quality of Care in 2014

  • 15th January 2015

- Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced ...

Search for Element 113 Concluded at Last

Search for Element 113 Concluded at Last

  • 27th September 2012

-     The most unambiguous data to date on the elusive 113th atomic element has been obtained by ...

Global Hypertension Experts Launch First-of-its-Kind Online Resource

Global Hypertension Experts Launch First-of-its-Kind Online Resource

  • 23rd August 2012

- The Power Over Pressure steering committee today announced the launch of the world's first online resource created to ...

Largest Comparative Study of Radioembolisation Shows SIR-Spheres Microspheres Significantly Improves

Largest Comparative Study of Radioembolisation Shows SIR-Spheres Microspheres Significantly Improves

  • 24th March 2012

-       - New Australian Data Provides Further Evidence of Survival Benefit for ...